Welcome to The Catalyst
Change isn't quick. Unless it's when you experience Intravascular Lithotripsy (IVL) for the first time. Stay apprised of our latest news and insights while discovering how a simple and intuitive tool can be The Catalyst to change the way you think about calcium modification.
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
Updated SCAI guidance includes Coronary IVL as a treatment option in all U.S. cath labs regardless of surgical backup status.
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
CMS Corrects Error for IVL Procedures in ASC Setting – Retroactive TPT Payment Eligible for 2022
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2, Reimbursement
Für eine deutschsprachige Version klicken Sie HIER
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2, Reimbursement
Verbesserte Kostenerstattung für koronare IVL in Deutschland
For an English language version, click HERE
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2, Reimbursement
Topics: Coronary IVL, IVL Technology, Coronary Clinical Data, Shockwave C2, Coronary Conferences, Treating Different Ca++ Morphologies, Female vs. Male Outcomes
Topics: Coronary IVL, IVL Technology, Coronary Clinical Data, Shockwave C2, Coronary Conferences, Treating Different Ca++ Morphologies, Female vs. Male Outcomes
It was smooth sailing for Shockwave this summer! Thank you to everyone who made Q3 unforgettable; but before we get cozy for the holidays, let’s reflect on the events that made the quarter one to remember. This year’s TCT was particularly momentous, as we announced the first prospective, female-only study of coronary interventions, EMPOWER CAD. We also explored tips and tricks for IVL with guide extension catheter usage with Dr. Stephan Heo and debated different approaches to modifying nodular calcium with an expert panel. Read up on the latest Shockwave IVL peer-written publications and more in the Q3 PulsePoint Newsletter.
Topics: Coronary IVL, Peripheral IVL, IVL Technology, Coronary Clinical Data, Peripheral Conferences, Peripheral Clinical Data, SWAV News, Shockwave C2, Coronary Conferences, Shockwave S4, PulsePoint Newsletter, Calcium Corner, Shockwave M5 & Shockwave M5+, Female vs. Male Outcomes, Empower CAD
In this short video, Dr. Sundeep Kalra, Royal Free Hospital of London, UK, shares his experience with Shockwave IVL, highlighting his evolution in the use of the technology since he started in 2016. At that time, his main indication for use of IVL was severely calcified coronary arteries with > 270° arc of calcium on intravascular imaging. Nowadays, Dr. Kalra uses Shockwave IVL to treat the whole lesion throughout all calcium morphologies, to ensure good plaque modification and achieve greater stent expansion.
Here, Dr. Kalra presents one of his recent clinical cases with Shockwave IVL: a 77-year-old woman with worsening stable angina and severe calcified LAD. The patient was treated with a 3.0mm Shockwave C2, using 50 shocks to fracture nodular calcium and 30 shocks for the eccentric plaque, followed by stent placement.
Topics: Coronary IVL, Coronary Clinical Data, Shockwave C2
Did you get a chance to watch the educational symposium on nodular calcium at TCT 2022? If you missed it, we’ve got you covered!
Topics: Coronary IVL, IVL Technology, Coronary Clinical Data, Shockwave C2, Coronary Conferences, Treating Different Ca++ Morphologies, Female vs. Male Outcomes
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
